NeuroSense targets December 2026 Canada filing for PrimeC ALS drug amid Phase 3 PARAGON preparations

Reuters2026/08/13 13:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NeuroSense set plans to launch the Phase 3 PARAGON trial of PrimeC in ALS, targeting about 300 participants, mainly in the US.
Financing became the gating item for PARAGON; management is pursuing funding tied to strategic support, including partner talks.
Regulatory strategy shifted to seek earlier market access in Canada, with a PrimeC New Drug Submission targeted for December 2026.
Workstreams broadened to evaluate additional territories for filings using existing data, alongside potential PrimeC development or commercialization partnerships.
Nasdaq compliance plan includes seeking more time, with board authority sought for a 1-for-4 to 1-for-40 reverse split if needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608130930PR_NEWS_USPR_____LN25906) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NeuroSense targets December 2026 Canada filing for PrimeC ALS drug amid Phase 3 PARAGON preparations

You may also like

Crypto prices